• 1
    Odeh M. New insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol 1997; 83: 10316.
  • 2
    Wolfe F, Rehman Q, Lane N, Kremer J. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. J Rheumatol 2001; 28: 170411.
  • 3
    Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999; 38: 1923.
  • 4
    Lipsky PE, van der Heijde D, St Clair WF, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 5
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 6
    Kavanaugh A, St. Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 84150.
  • 7
    Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 8
    Fries J, Spitz P, Young D. The dimensions of health outcomes: the health assessment questionnaire, disability, and pain scales. J Rheumatol 1982; 9: 78993.
  • 9
    Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 10
    Ware JJ, Kosinski M, Keller S. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute; 1994.
  • 11
    Van der Heijde D, van Leeuwen M, van Riel P, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 2634.
  • 12
    Van der Heijde. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 2613.
  • 13
    Van der Heijde D, Dankert T, Nieman F, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 9417.
  • 14
    Felson D, Anderson J, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 15
    Conover WJ. Practical nonparametric statistics. New York: John Wiley & Sons; 1980.
  • 16
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiologic Health (CDRH). Guidance for Industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). Clin 7; Washington. February 1999.
  • 17
    Wells G, Tugwell P, Kraag G, Baker P, Groh J, Redelmeier D. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 18
    Redelmeier D, Lorig K. Assessing the clinical importance of symptomatic improvements: an illustration in rheumatology. Arch Intern Med 1993; 153: 133742.
  • 19
    Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 275161.
  • 20
    Kosinski M, Zhai S, Dedhiya S, Osterhaus J, Ware JJ. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 147887.
  • 21
    McHorney C, Ware JJ, Lu J, Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 4066.
  • 22
    Boueri F, Bucher-Bartelson B, Glenn K, Make B. Quality of life measured with a generic instrument (Short Form-36) improves following pulmonary rehabilitation in patients with COPD. Chest 2001; 119: 7784.
  • 23
    Kaasa S, Knobel H, Loge J, Hjermstad M. Hodgkin's disease: quality of life in future trials. Ann Oncol 1998; 9: 13745.
  • 24
    Wolfe F. The burden of rheumatoid arthritis: based on a presentation by Frederick Wolfe, MD. Am J Managed Care 1999; 5 Suppl 14: S8529.
  • 25
    Pincus T, Callahan L. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis: lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 1990; 17: 15825.
  • 26
    Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 185460.
  • 27
    Welsing P, van Gestel A, Swinkels H, Kiemeney L, van Riel P. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 200917.
  • 28
    Hulsmans H, Jacobs J, van der Heijde D, van Albada-Kuipers G, Schenk Y, Bijlsma J. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000; 43: 192740.
  • 29
    Wolfe F, Sharp J. Radiographic outcome of recent-onset rheumatoid arthritis. Arthritis Rheum 1998; 41: 157182.
  • 30
    Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9: 61932.
  • 31
    Parker S, Tong T, Bolder S, Wingo P. Cancer statistics. CA Cancer J Clin 1997; 47: 527.
  • 32
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al, for the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 102935.
  • 33
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000; 43: 228390.
  • 34
    Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14 Suppl C: 2932C.